Celgene have announced that Chief Operating Officer Scott Smith is leaving the company, effective immediately. The biopharma company did not cite a reason for his departure but the announcement comes weeks after the FDA turned down Celgene’s high-profile MS drug.
Chief executive officer Mark Alles will assume Smith’s responsibilities. Alles is now directly responsible for all major parts of its business.
Smith joined Celgene in 2008 and served as its president and chief operating officer since April 2017.
Read the Reuters report